颈动脉产品介绍 - 支架-in service

CarotidWALLSTENTTM颈动脉支架,支架自膨支架Elgiloy金属丝编制管状网眼结构,2,支架输送系统Monorail导管设计，0.014“导丝输送系统；5F(672:863866,目前为止，已经完成3项有关颈动脉支架设计与临床结果的回顾性、非随机研究。DoesFreeCellAreaInfluencetheOutcomeinCarotidArteryStenting?Bosiersetal.Aretrospectiveanalysisof30dayoutcomesofacarotidarterystentingmulticenterdatabaseconsistingof3179consecutivepatientsSPACE,aretrospective,randomizedtrialofcarotidarterystentingversusendarterectomyinstandardsurgicalriskpatientswithsymptomaticcarotidarterystenosesSchillingerM,GschwendtnerM,ReimersB,etal.Doescarotidstentcelldesignmatter?Aretrospective,nonrandomizedreviewofacarotidarterystentingmulticenterdatabaseconsistingof1,684consecutivepatients,DoesCarotidStentDesignInfluenceOutcomes?Bersin.CatheterizationandCardiovascularInterventions2008;72:863866.,DoesFreeCellAreaInfluencetheOutcomeinCarotidArteryStenting?Bosiersetal.EurJVascEndovascSurg2007;33:135-141.,目的:明确颈动脉支架设计，尤其是支架网孔面积，对于颈动脉支架术后30天卒中、死亡或TIA的影响。30天结果的回顾性分析TIA，死亡,大和小卒中(非心肌梗死)共3179接受颈动脉支架手术的患者4个中心Bosiers,Deloose-BelgiumPeeters,Verbis-BelgiumSetacci,Donatoetal.-ItalyCremonesi,Castriota-Italy,DoesFreeCellAreaInfluencetheOutcomeinCarotidArteryStenting?Bosiersetal.EurJVascEndovascSurg2007;33:135-141.,DoesFreeCellAreaInfluencetheOutcomeinCarotidArteryStenting?Bosiersetal.EurJVascEndovascSurg2007;33:135-141.,闭环支架定义为支架网孔面积5.0mm2例如PreciseRxNitinolStentSystemRXAcculinkCarotidStent,DoesFreeCellAreaInfluencetheOutcomeinCarotidArteryStenting?Bosiersetal.EurJVascEndovascSurg2007;33:135-141.,PreciseisatrademarkofCordisCorporation,AcculinkisatrademarkofAbbottCardiovascularSystems,Inc,andXactistrademarkofMedNova,Ltd.,第30天事件：闭环vs.开环支架设计TIA,死亡,大和小卒中,DoesFreeCellAreaInfluencetheOutcomeinCarotidArteryStenting?Bosiersetal.EurJVascEndovascSurg2007;33:135-141.,对于症状性患者，术后第30天的主要事件发生率差异显著开环支架设计(7.0%)VS闭环支架设计(2.2%)(p0.0001),DoesFreeCellAreaInfluencetheOutcomeinCarotidArteryStenting?Bosiersetal.EurJVascEndovascSurg2007;33:135-141.,N=3179P=0.005,N=1317P0.0001,N=1862P=1.0,DoesFreeCellAreaInfluencetheOutcomeinCarotidArteryStenting?Bosiersetal.EurJVascEndovascSurg2007;33:135-141.,术后=(TIA,卒中,死亡)直到术后30天发生闭环vs.开环支架设计,DoesFreeCellAreaInfluencetheOutcomeinCarotidArteryStenting?Bosiersetal.EurJVascEndovascSurg2007;33:135-141.,对于症状性患者，手术30天以后的主要事件发生率差异显著开环支架设计(6.3%)VS闭环支架设计(1.3%)(p0.0001),N=3179P0.0001,N=1317P0.0001,N=1862P=1.0,患者评估由独立神经病学医师进行神经学上的局限性回顾性的研究非随机设计可能导致在选择时会因特定病变类型有所偏向注册数据受制于自我审计技术复杂性没有评估，结果没有经过风险校正有必要进行前瞻性的随机研究来比较不同支架网孔面积以得到最终结论,DoesFreeCellAreaInfluencetheOutcomeinCarotidArteryStenting?Bosiersetal.EurJVascEndovascSurg2007;33:135-141.,DoesFreeCellAreaInfluencetheOutcomeinCarotidArteryStenting?Bosiersetal.EurJVascEndovascSurg2007;33:135-141.,总结,四个中心的30天结果回顾性分析N=3179CASpatients对于症状性患者，术后第30天的主要事件发生率差异显著，开环支架设计(7.0%)VS闭环支架设计(2.2%)(p0.0001)对于症状性患者，手术30天以后的主要事件发生率差异显著，开环支架设计(6.3%)VS闭环支架设计(1.3%)(p0.0001),DoesFreeCellAreaInfluencetheOutcomeinCarotidArteryStenting?Bosiersetal.EurJVascEndovascSurg2007;33:135-141.,DoesFreeCellAreaInfluencetheOutcomeinCarotidArteryStenting?Bosiersetal.EurJVascEndovascSurg2007;33:135-141.,CarotidWALLSTENTEndoprosthesis,闭环设计跟踪性极佳的SDS-支架输送系统卓越的显影性独特的可回收能力*唯一经FDA批准可用于双侧治疗颈动脉支架*临床数据支持,*Pleasenotethatreconstrainmentandrepositioningaresubjecttospecificlimitations.PleaserefertoDFUcautionsandwarningsforadditionalinformation.*TheCarotidWALLSTENTEndoprosthesisisindicatedforuseineligiblepatientswithipsilateralorbilateralcarotidarterydisease,跟踪性极佳的SDS-支架输送系统,独特的编织结构提高支架的柔顺性,CarotidWALLSTENT具有高度柔顺的输送系统，提供卓越的跟踪性以通过扭曲病变,TestingperformedonCarotidWALLSTENTEndoprosthesis8mmx21mm,PreciseProRX8mmx40mm,RXACCULINK7-10mmx40mm,Xact7-9mmx40mm.Benchtestresultsmaynotnecessarilybeindicativeofclinicalperformance.Testresultsshownareformodelsdeemedmosttypicallyselectedforplacementincommoncarotidarterywithareferencediameterof8mm.Othermodelswerealsotestedandyieldedsimilarresults.N=3.Dataonfile.PreciseProisatrademarkofCordisCorporation,AcculinkisatrademarkofAbbottCardiovascularSystems,Inc,andXactistrademarkofMedNova,Ltd.,DeliveryForce:Benchtestthatmeasuresthemaximumforcerequiredtonavigatethroughabenchmodeloftortuosity.Smallervalues=Lessforcerequired,低外廓的输送系统,匹配的导引鞘*(VesselSize),*InformationexcerptedfromrespectiveDFUs.,PreciseProisatrademarkofCordisCorporation,AcculinkisatrademarkofAbbottCardiovascularSystems,Inc,andXactistrademarkofMedNova,Ltd.,低外廓设计允许其通过5For6F血管鞘,CarotidWALLSTENT的低外廓支架输送系统使其具有卓越的跟踪性以通过迂曲的解剖结构,便于使用,Thepin-and-pulldeliverysystemisdesignedtosimplifydelivery,CarotidWALLSTENTEndoprosthesisDeliverySystemFinalAssembly.ImagepropertyofBostonScientificCorporation.Notnecessarilytoscale.,闭环设计跟踪性极佳的SDS-支架输送系统卓越的显影性独特的可回收能力*唯一经FDA批准可用于双侧治疗颈动脉支架*临床数据支持,*Pleasenotethatreconstrainmentandrepositioningaresubjecttospecificlimitations.PleaserefertoDFUcautionsandwarningsforadditionalinformation.*TheCarotidWALLSTENTEndoprosthesisisindicatedforuseineligiblepatientswithipsilateralorbilateralcarotidarterydisease,CarotidWALLSTENTTM颈动脉支架,出色的显影性,在对比测试中，与其他颈动脉支架相比，CarotidWALLSTENT是显影性最好的支架,CarotidWALLSTENT的设计使支架具有高度可视性，便于支架的精确释放,TestingperformedonCarotidWALLSTENTEndoprosthesis8mmx21mm,PreciseProRX8mmx40mm,RXACCULINK7-10mmx40mm,Xact7-9mmx40mm.Benchtestresultsmaynotnecessarilybeindicativeofclinicalperformance.Testresultsshownareformodelsdeemedmosttypicallyselectedforplacementincommoncarotidarterywithareferencediameterof8mm.Othermodelswerealsotestedandyieldedsimilarresults.N=3.Dataonfile.PreciseProisatrademarkofCordisCorporation,AcculinkisatrademarkofAbbottCardiovascularSystems,Inc,andXactistrademarkofMedNova,Ltd.,Radiopacity:BenchtestthatillustratesthevisibilityofastentunderC-armunderneathsimulatedtissue,ImagecourtesyofDr.HoffmanIllustratestheinvivovisibilityofCarotidWALLSTENTandtheRxAcculinkCarotidstent.Maynotbeindicativeofclinicalperformance.,.AcculinkisatrademarkofAbbottCardiovascularSystems,Inc,CarotidWALLSTENTEndoprosthesis,RXAcculinkCarotidStent,出色的显影性,出色的显影性,DistalInnerROMarker,OuterDistalROMarker,AllPhotographstakenbyBostonScientificCorporation,内杆及外鞘上的可回收标记点均不透射线，帮助支架的定位,闭环设计跟踪性极佳的SDS-支架输送系统卓越的显影性独特的可回收能力*唯一经FDA批准可用于双侧治疗颈动脉支架*临床数据支持,*Pleasenotethatreconstrainmentandrepositioningaresubjecttospecificlimitations.PleaserefertoDFUcautionsandwarningsforadditionalinformation.*TheCarotidWALLSTENTEndoprosthesisisindicatedforuseineligiblepatientswithipsilateralorbilateralcarotidarterydisease,CarotidWALLSTENTTM颈动脉支架,独特的可回收能力*,*Pleasenotethatreconstrainmentandrepositioningaresubjecttospecificlimitations.PleaserefertoDFUcautionsandwarningsforadditionalinformation.,CarotidWALLSTENT的独特设计使其可以重新回收再释放，帮助支架的精确释放,独特的导管结构和支架设计使支架在其在释放少于50%时都可以回收再释放,DFU中与回收相关的注意事项*:只有在必要时才进行回收当支架已解除斑块时，应该严格避免回收回收次数不能超过2次,不可回收标记点,CarotidWALLSTENTEndoprosthesisDeliverySystemFinalAssembly.ImagepropertyofBostonScientificCorporation.Notnecessarilytoscale.,*Pleasenotethatreconstrainmentandrepositioningaresubjecttospecificlimitations.PleaserefertoDFUcautionsandwarningsforadditionalinformation.,独特的可回收能力*,显示支架回缩的“不可回收点”只要外鞘的回撤未超过不可回收标记点，医生都可以对支架进行回收重新释放（不超过2次，未接触斑块）,闭环设计跟踪性极佳的SDS-支架输送系统卓越的显影性独特的可回收能力*唯一经FDA批准可用于双侧治疗颈动脉支架*临床数据支持,*Pleasenotethatreconstrainmentandrepositioningaresubjecttospecificlimitations.PleaserefertoDFUcautionsandwarningsforadditionalinformation.*TheCarotidWALLSTENTEndoprosthesisisindicatedforuseineligiblepatientswithipsilateralorbilateralcarot